NCTId,final_date,start_date,change,final_value,start_value
NCT01484678,2025-10-20 07:24:46.633691,2025-10-13 07:24:44.496989,Primary Completion Date,2026-08-31,2025-08-31
NCT01484678,2025-10-20 07:24:46.633691,2025-10-13 07:24:44.496989,Completion Date,2026-08-31,2025-08-31
NCT01484678,2025-10-20 07:24:46.633691,2025-10-13 07:24:44.496989,Last Update Post Date,2025-10-15,2025-07-09
NCT02500381,2025-09-29 07:24:18.405365,2025-09-22 07:24:44.677743,Last Update Post Date,2025-09-23,2024-12-16
NCT03362502,2025-09-22 07:24:44.677743,2025-09-15 07:24:11.470430,Overall Status,TERMINATED,ACTIVE_NOT_RECRUITING
NCT03362502,2025-09-22 07:24:44.677743,2025-09-15 07:24:11.470430,Completion Date,2025-07-28,2025-08-29
NCT03362502,2025-09-22 07:24:44.677743,2025-09-15 07:24:11.470430,Last Update Post Date,2025-09-15,2025-07-30
NCT03368742,2025-09-15 07:24:11.470430,2025-09-08 07:23:27.695799,Last Update Post Date,2025-09-09,2025-08-03
NCT03368742,2025-11-03 07:24:26.813865,2025-10-27 07:23:55.233479,Last Update Post Date,2025-10-31,2025-09-09
NCT03863119,2025-10-06 07:23:59.452506,2025-09-29 07:24:18.405365,Overall Status,AVAILABLE,APPROVED_FOR_MARKETING
NCT03863119,2025-10-06 07:23:59.452506,2025-09-29 07:24:18.405365,Brief Summary,"The intent of this protocol is to provide continued access to vamorolone for subjects in the United States and Canada who have completed the VBP15-LTE, VBP15- 004, or VBP15-006 protocols (and are thereby ineligible to enroll in another trial of vamorolone therapy), during the time a new drug application for vamorolone is under preparation and review.","The intent of this protocol is to provide continued access to vamorolone for subjects in the United States who Have Completed the VBP15-LTE, VBP15- 004, or VBP15-006 protocols (and are thereby ineligible to enroll in another trial of vamorolone therapy), during the time a new drug application for vamorolone is under preparation and review."
NCT03863119,2025-10-06 07:23:59.452506,2025-09-29 07:24:18.405365,Last Update Post Date,2025-09-30,2025-02-10
NCT03936894,2025-10-06 07:23:59.452506,2025-09-29 07:24:18.405365,Overall Status,UNKNOWN,ACTIVE_NOT_RECRUITING
NCT04240314,2025-09-15 07:24:11.470430,2025-09-08 07:23:27.695799,Overall Status,COMPLETED,ACTIVE_NOT_RECRUITING
NCT04240314,2025-09-15 07:24:11.470430,2025-09-08 07:23:27.695799,Has Results,True,False
NCT04240314,2025-09-15 07:24:11.470430,2025-09-08 07:23:27.695799,Primary Outcome Measure,Number of Participants With Unacceptable Toxicity.,Monitoring for the development of unacceptable toxicity.
NCT04240314,2025-09-15 07:24:11.470430,2025-09-08 07:23:27.695799,Secondary Outcome Measure,"Change in Dystrophin Expression From Baseline Following Treatment With scAAV9.U7.ACCA., Change in Dystrophin Expression From Baseline Following Treatment With scAAV9.U7.ACCA., Changes in Percent of Exon 2 Skipping/Exclusion in the Dystrophin mRNA Transcript.","Change in dystrophin expression from baseline following treatment with scAAV9.U7.ACCA., Change in dystrophin expression from baseline following treatment with scAAV9.U7.ACCA., Changes in exon 2 inclusion in the dystrophin mRNA transcript."
NCT04240314,2025-09-15 07:24:11.470430,2025-09-08 07:23:27.695799,Collaborator Name,"Audentes Therapeutics, Astellas Pharma Inc",Audentes Therapeutics
NCT04240314,2025-09-15 07:24:11.470430,2025-09-08 07:23:27.695799,Primary Completion Date,2023-11-13,2023-11-19
NCT04240314,2025-09-15 07:24:11.470430,2025-09-08 07:23:27.695799,Completion Date,2025-07-01,2025-11-19
NCT04240314,2025-09-15 07:24:11.470430,2025-09-08 07:23:27.695799,Last Update Post Date,2025-09-11,2023-02-09
NCT04281485,2025-10-27 07:23:55.233479,2025-10-20 07:24:46.633691,Last Update Post Date,2025-10-20,2025-09-03
NCT04428476,2025-11-10 07:23:57.616684,2025-11-03 07:24:26.813865,Brief Summary,"This Phase 2, multi-center, open-label extension trial will provide deramiocel (CAP-1002) to subjects that were enrolled in the HOPE-2 trial and completed 12 months of follow-up. The trial will explore the safety and efficacy of twenty intravenous administrations of deramiocel, each separated by three months, over a period of approximately 60 months. Following completion of the initial open-label phase (Month 60), subjects who have completed all Month 60 assessments will be eligible to continue into a long-term open label extension (LT-OLE) period and can continue to receive deramiocel once every 3 months until deramiocel is commercially available or the sponsor terminates the study, or the subject withdraws consent or study participation is terminated by the sponsor.
Subjects will undergo a targeted screening during a 30-day screening period, eligible subjects will then undergo baseline safety and efficacy assessments on Day 1 prior to their first infusion of deramiocel.
Subjects will complete trial assessments at Screening; Day 1; Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, and all LT-OLE visits. Safety and efficacy assessments will be conducted prior to deramiocel administration at the Day 1, Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, and at all LT-OLE trial visits, unless otherwise indicated.
All deramiocel infusions will be conducted in an outpatient setting at the investigative site on Day 1 and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, with continued dosing in the LT-OLE visits. Subjects will be observed in the outpatient setting for at least two hours post infusion and then discharged the same day, if medically cleared by the site Investigator.","This Phase 2, multi-center, open-label extension trial will provide deramiocel (CAP-1002) to subjects that were enrolled in the HOPE-2 trial and completed 12 months of follow-up. The trial will explore the safety and efficacy of twenty intravenous administrations of deramiocel, each separated by three months. Subjects will undergo a targeted screening during a 30-day screening period, eligible subjects will then undergo baseline safety and efficacy assessments on Day 1 prior to their first infusion of deramiocel.
Subjects will complete trial assessments at Screening; Day 1; Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, and 60. Safety and efficacy assessments will be conducted prior to deramiocel administration at the Day 1, Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, and 57 trial visits, unless otherwise indicated.
All deramiocel infusions will be conducted in an outpatient setting at the investigative site on Day 1 and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, and 57. Subjects will be observed in the outpatient setting for at least two hours post infusion and then discharged the same day, if medically cleared by the site Investigator."
NCT04428476,2025-11-10 07:23:57.616684,2025-11-03 07:24:26.813865,Completion Date,2026-05-01,2026-03-01
NCT04428476,2025-11-10 07:23:57.616684,2025-11-03 07:24:26.813865,Last Update Post Date,2025-11-03,2025-07-03
NCT04433234,2025-09-22 07:24:44.677743,2025-09-15 07:24:11.470430,Last Update Post Date,2025-09-19,2024-08-29
NCT04587908,2025-09-15 07:24:11.470430,2025-09-08 07:23:27.695799,Last Update Post Date,2025-09-11,2024-08-14
NCT04906460,2025-09-29 07:24:18.405365,2025-09-22 07:24:44.677743,Brief Summary,"This is a Phase 1b/2 open-label study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical effects of intravenous (IV) WVE-N531 in patients with Duchenne muscular dystrophy (DMD). To participate in the study, patients must have a documented mutation of the DMD gene that is amenable to exon 53 skipping intervention. This study has 3 parts, Part A, Part B, including Part B Extension Arm, and Part C. Part A is completed. Part B is completed. Following completion of Part B, all patients elected to continue to receive study drug in the optional Part B open-label Extension Arm. Part C has been added to the study and will enroll new patients.","This is a Phase 1b/2 open-label study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical effects of intravenous (IV) WVE-N531 in patients with Duchenne muscular dystrophy (DMD). To participate in the study, patients must have a documented mutation of the DMD gene that is amenable to exon 53 skipping intervention. This study has 2 parts, Part A and Part B. Part A is completed. Part B is completed. Following completion of Part B, all patients have elected to continue to receive study drug in an optional open-label extension arm."
NCT04906460,2025-09-29 07:24:18.405365,2025-09-22 07:24:44.677743,Primary Outcome Measure,"Part A: Safety: Proportion of patients with adverse events (AEs), Part B: Pharmacodynamics: Dystrophin level (% normal dystrophin) as assessed by Western blot of muscle tissue following multiple doses of WVE-N531, Part C: Pharmacodynamics: Change from baseline dystrophin level (% normal dystrophin) as assessed by a validated assay analysis in muscle tissue following multiple doses of WVE-N531",Pharmacodynamics: Dystrophin level (% normal dystrophin) as assessed by Western blot of muscle tissue following multiple doses of WVE-N531
NCT04906460,2025-09-29 07:24:18.405365,2025-09-22 07:24:44.677743,Secondary Outcome Measure,"Part A: Pharmacokinetics: Concentration of WVE-N531 in muscle tissue, Part A: Pharmacodynamics: Dystrophin level (% normal dystrophin) as assessed by Western blot of muscle tissue following multiple doses of WVE-N531, Part B: North Star Ambulatory Assessment (NSAA) (Version 2.0), including time to stand and a timed 10-meter walk/run, with a range of 0 to 34 where higher scores indicate better outcome., Part B: Performance of the Upper Limb (PUL) (Version 2.0) with a range of 0 to 64 where higher scores indicate a better outcome., Part B: Stride Velocity 95th Centile (SV95C)/upper limb outcome (non-ambulatory patients), Part C: North Star Ambulatory Assessment (NSAA) (Version 2.0), including time to stand and a timed 10-meter walk/run, with a range of 0 to 34 where higher scores indicate better outcome., Part C: Performance of the Upper Limb (PUL) (Version 2.0) with a range of 0 to 64 where higher scores indicate a better outcome., Part C: Stride Velocity 95th Centile (SV95C)/upper limb outcome (non-ambulatory patients)","North Star Ambulatory Assessment (NSAA) (Version 2.0), including time to stand and a timed 10-meter walk/run, with a range of 0 to 34 where higher scores indicate better outcome., Performance of the Upper Limb (PUL) (Version 2.0) with a range of 0 to 64 where higher scores indicate a better outcome., Stride Velocity 95th Centile (SV95C)/upper limb outcome (non-ambulatory patients)"
NCT04906460,2025-09-29 07:24:18.405365,2025-09-22 07:24:44.677743,Minimum Age,4 Years,5 Years
NCT04906460,2025-09-29 07:24:18.405365,2025-09-22 07:24:44.677743,Enrollment Count,26.0,11.0
NCT04906460,2025-09-29 07:24:18.405365,2025-09-22 07:24:44.677743,Primary Completion Date,2026-06-27,2025-01-16
NCT04906460,2025-09-29 07:24:18.405365,2025-09-22 07:24:44.677743,Completion Date,2027-04-24,2026-10-01
NCT04906460,2025-09-29 07:24:18.405365,2025-09-22 07:24:44.677743,Last Update Post Date,2025-09-24,2025-02-19
NCT04906460,2025-10-13 07:24:44.496989,2025-10-06 07:23:59.452506,Overall Status,RECRUITING,ACTIVE_NOT_RECRUITING
NCT04906460,2025-10-13 07:24:44.496989,2025-10-06 07:23:59.452506,Last Update Post Date,2025-10-06,2025-09-24
NCT05016908,2025-11-03 07:24:26.813865,2025-10-27 07:23:55.233479,Overall Status,UNKNOWN,RECRUITING
NCT05166109,2025-09-22 07:24:44.677743,2025-09-15 07:24:11.470430,Overall Status,COMPLETED,ACTIVE_NOT_RECRUITING
NCT05166109,2025-09-22 07:24:44.677743,2025-09-15 07:24:11.470430,Enrollment Count,46.0,39.0
NCT05166109,2025-09-22 07:24:44.677743,2025-09-15 07:24:11.470430,Primary Completion Date,2025-08-18,2025-06-30
NCT05166109,2025-09-22 07:24:44.677743,2025-09-15 07:24:11.470430,Completion Date,2025-08-18,2025-06-30
NCT05166109,2025-09-22 07:24:44.677743,2025-09-15 07:24:11.470430,Last Update Post Date,2025-09-18,2024-12-27
NCT05185622,2025-10-27 07:23:55.233479,2025-10-20 07:24:46.633691,Has Results,True,False
NCT05185622,2025-10-27 07:23:55.233479,2025-10-20 07:24:46.633691,Primary Outcome Measure,"Number of Participants With Any Adverse Events as Assessed by Common Terminology Criteria for Adverse Events Version 4.03 (CTCAE v4.03), Number of Participants With Drug Related Adverse Events as Assessed by Common Terminology Criteria for Adverse Events Version 4.03 (CTCAE v4.03), Number of Participants With Severe Adverse Events as Assessed by Common Terminology Criteria for Adverse Events Version 4.03 (CTCAE v4.03), Number of Participants With Serious Adverse Events as Assessed by Common Terminology Criteria for Adverse Events Version 4.03 (CTCAE v4.03), Number of Participants With Adverse Events as Assessed by Common Terminology Criteria for Adverse Events Version 4.03 (CTCAE v4.03) Leading to Study Treatment Discontinuation, Change in Height (Absolute) From Baseline to Week 12, Change in Height (Percentile) From Baseline to Week 12, Change in Height (Z-score) From Baseline to Week 12, Change in Weight (Absolute) From Baseline to Week 12, Change in Weight (Percentile) From Baseline to Week 12, Change in Weight (Z-score) From Baseline to Week 12, Change in Body Mass Index (BMI) (Absolute) From Baseline to Week 12, Change in Body Mass Index (BMI) (Percentile) From Baseline to Week 12, Change in Body Mass Index (BMI) (Z-score) From Baseline to Week 12, Change in Diastolic Blood Pressure, Change in Systolic Blood Pressure, Number of Participants With Treatment Emergent Cushingoid Features, Number of Participants With Clinically Significant Treatment-emergent Abnormal Clinical Laboratory Test Result, Categorical Analysis of QTcF at Week 12, Number of Eyes With Cataract, Number of Eyes With Glaucoma","Change in Body Mass Index (BMI) from baseline to Week 12, Change in Body Mass Index (BMI) z-score from baseline to Week 12, Change in Weight from baseline to each of the scheduled on treatment and post-treatment assessment time points, Change in Height from baseline to Week 12, Change in Height z score from baseline to Week 12, Change in sitting blood pressure from baseline to each of the scheduled on-treatment and post-treatment assessment time points, Change in heart rate from baseline to each of the scheduled on-treatment and post-treatment assessment time points, Change in respiratory rate from baseline to each of the scheduled on-treatment and post-treatment assessment time points, Change in body temperature from baseline to each of the scheduled on-treatment and post-treatment assessment time points, Number of participants with Cushingoid features, Number of participants with abnormal blood laboratory test results, Number of participants with abnormal urine laboratory test results, Number of participants with abnormal ECGs, Number of participants with Glaucoma, Number of participants with Cataracts, Number of Participants with Adverse Events as Assessed by Common Terminology Criteria for Adverse Events version 4.03 (CTCAE v4.03)"
NCT05185622,2025-10-27 07:23:55.233479,2025-10-20 07:24:46.633691,Secondary Outcome Measure,"Pre-dose and Post-dose Plasma Concentration Measurements of Vamorolone at Day 1 and Week 2, Descriptive Statistics of PK Parameters - Tmax, Descriptive Statistics of PK Parameters - Cmax, Descriptive Statistics of PK Parameters in Subjects Aged 2 to 4 Years - AUC 0-6, Descriptive Statistics of PK Parameters in Subjects Aged 7 to 18 Years - AUC 0-inf","Area under the Curve infinity (AUCinf) following oral administration, Change in morning cortisol concentration from baseline to Week 12, Change in fasting serum concentration of glucose from baseline to Week 12, Change in fasting serum concentration of insulin from baseline to Week 12, Change in serum concentration of hemoglobin A1c (HbA1c) from baseline to Week 12"
NCT05185622,2025-10-27 07:23:55.233479,2025-10-20 07:24:46.633691,Last Update Post Date,2025-10-24,2024-10-16
NCT05291091,2025-09-29 07:24:18.405365,2025-09-22 07:24:44.677743,Brief Summary,"A study of sevasemten (EDG-5506) in Becker muscular dystrophy (known as CANYON) and pivotal cohort (known as GRAND CANYON). The EDG-5506-201 CANYON study was expanded to include an additional 120 adult participants in a cohort called GRAND CANYON, that is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of sevasemten in adults with Becker.
CANYON and GRAND CANYON are fully enrolled.","A study of sevasemten (EDG-5506) in Becker muscular dystrophy (known as CANYON) and pivotal cohort (known as GRAND CANYON). The EDG-5506-201 CANYON study was expanded to include an additional 120 adult participants in a cohort called GRAND CANYON, that is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of sevasemten in adults with Becker.
CANYON is fully enrolled; GRAND CANYON is currently enrolling."
NCT05291091,2025-09-29 07:24:18.405365,2025-09-22 07:24:44.677743,Last Update Post Date,2025-09-25,2025-09-03
NCT05291091,2025-11-10 07:23:57.616684,2025-11-03 07:24:26.813865,Last Update Post Date,2025-11-03,2025-09-25
NCT05429372,2025-10-27 07:23:55.233479,2025-10-20 07:24:46.633691,Overall Status,TERMINATED,ACTIVE_NOT_RECRUITING
NCT05429372,2025-10-27 07:23:55.233479,2025-10-20 07:24:46.633691,Primary Completion Date,2025-10-03,2025-09-19
NCT05429372,2025-10-27 07:23:55.233479,2025-10-20 07:24:46.633691,Completion Date,2025-10-03,2025-09-19
NCT05429372,2025-10-27 07:23:55.233479,2025-10-20 07:24:46.633691,Last Update Post Date,2025-10-21,2025-09-03
NCT05464446,2025-09-22 07:24:44.677743,2025-09-15 07:24:11.470430,Lead Sponsor Name,Lokman Hekim University,Lokman Hekim Üniversitesi
NCT05689164,2025-10-27 07:23:55.233479,2025-10-20 07:24:46.633691,Overall Status,TERMINATED,ACTIVE_NOT_RECRUITING
NCT05689164,2025-10-27 07:23:55.233479,2025-10-20 07:24:46.633691,Primary Completion Date,2025-09-24,2025-09-05
NCT05689164,2025-10-27 07:23:55.233479,2025-10-20 07:24:46.633691,Completion Date,2025-09-24,2025-09-05
NCT05689164,2025-10-27 07:23:55.233479,2025-10-20 07:24:46.633691,Last Update Post Date,2025-10-21,2025-09-03
NCT05693142,2025-09-15 07:24:11.470430,2025-09-08 07:23:27.695799,Brief Summary,"RGX-202 is a gene therapy designed to deliver a transgene for a novel microdystrophin that includes functional elements of naturally-occurring dystrophin including the C-Terminal (CT) domain.
This is a multicenter, open-label dose evaluation clinical study to assess the safety, tolerability, and clinical efficacy of a one-time intravenous (IV) dose of RGX-202 in participants with Duchenne.
For additional information on how to participate (or be considered for the study), please follow this link: https://mytomorrows.com/trials/affinity-duchenne","RGX-202 is a gene therapy designed to deliver a transgene for a novel microdystrophin that includes functional elements of naturally-occurring dystrophin including the C-Terminal (CT) domain.
This is a multicenter, open-label dose evaluation clinical study to assess the safety, tolerability, and clinical efficacy of a one-time intravenous (IV) dose of RGX-202 in participants with Duchenne."
NCT05693142,2025-09-15 07:24:11.470430,2025-09-08 07:23:27.695799,Last Update Post Date,2025-09-10,2025-08-13
NCT05693142,2025-10-13 07:24:44.496989,2025-10-06 07:23:59.452506,Last Update Post Date,2025-10-08,2025-09-10
NCT05996003,2025-09-22 07:24:44.677743,2025-09-15 07:24:11.470430,Condition,"Duchenne Muscular Dystrophy, Exon 44, DMD",Duchenne Muscular Dystrophy
NCT05996003,2025-09-22 07:24:44.677743,2025-09-15 07:24:11.470430,Last Update Post Date,2025-09-16,2025-06-05
NCT06013839,2025-10-06 07:23:59.452506,2025-09-29 07:24:18.405365,Overall Status,UNKNOWN,RECRUITING
NCT06053814,2025-09-15 07:24:11.470430,2025-09-08 07:23:27.695799,Last Update Post Date,2025-09-10,2024-12-17
NCT06066580,2025-11-10 07:23:57.616684,2025-11-03 07:24:26.813865,Last Update Post Date,2025-11-03,2025-09-03
NCT06079736,2025-10-06 07:23:59.452506,2025-09-29 07:24:18.405365,Overall Status,TERMINATED,ACTIVE_NOT_RECRUITING
NCT06079736,2025-10-06 07:23:59.452506,2025-09-29 07:24:18.405365,Primary Completion Date,2025-08-28,2025-04-01
NCT06079736,2025-10-06 07:23:59.452506,2025-09-29 07:24:18.405365,Completion Date,2025-08-28,2027-04-01
NCT06079736,2025-10-06 07:23:59.452506,2025-09-29 07:24:18.405365,Last Update Post Date,2025-10-01,2025-03-04
NCT06093100,2025-11-10 07:23:57.616684,2025-11-03 07:24:26.813865,Last Update Post Date,2025-11-06,2025-08-07
NCT06100887,2025-11-10 07:23:57.616684,2025-11-03 07:24:26.813865,Secondary Outcome Measure,"Incidence of laboratory test-related treatment emergent adverse events, Pharmacokinetics as measured by steady state plasma concentration, Change from Baseline in serum creatine kinase, Change from Baseline in fast skeletal muscle troponin I","Incidence of abnormal clinical chemistry test results, Incidence of abnormal hematology test results, Incidence of abnormal coagulation test results, Incidence of abnormal urinalysis test results, Pharmacokinetics as measured by steady state plasma concentration, Change from Baseline in serum creatine kinase, Change from Baseline in fast skeletal muscle troponin I"
NCT06100887,2025-11-10 07:23:57.616684,2025-11-03 07:24:26.813865,Primary Completion Date,2027-03-01,2025-10-01
NCT06100887,2025-11-10 07:23:57.616684,2025-11-03 07:24:26.813865,Completion Date,2027-03-01,2025-10-01
NCT06100887,2025-11-10 07:23:57.616684,2025-11-03 07:24:26.813865,Last Update Post Date,2025-11-06,2025-05-18
NCT06103006,2025-09-22 07:24:44.677743,2025-09-15 07:24:11.470430,Lead Sponsor Name,Lokman Hekim University,Lokman Hekim Üniversitesi
NCT06128564,2025-10-06 07:23:59.452506,2025-09-29 07:24:18.405365,Last Update Post Date,2025-10-02,2025-09-03
NCT06128564,2025-11-10 07:23:57.616684,2025-11-03 07:24:26.813865,Primary Completion Date,2034-01-30,2033-05-30
NCT06128564,2025-11-10 07:23:57.616684,2025-11-03 07:24:26.813865,Completion Date,2034-01-30,2033-05-30
NCT06128564,2025-11-10 07:23:57.616684,2025-11-03 07:24:26.813865,Last Update Post Date,2025-11-03,2025-10-02
NCT06138639,2025-09-15 07:24:11.470430,2025-09-08 07:23:27.695799,Last Update Post Date,2025-09-09,2025-08-24
NCT06138639,2025-10-20 07:24:46.633691,2025-10-13 07:24:44.496989,Last Update Post Date,2025-10-14,2025-09-09
NCT06270719,2025-10-13 07:24:44.496989,2025-10-06 07:23:59.452506,Last Update Post Date,2025-10-07,2025-08-11
NCT06412328,2025-09-22 07:24:44.677743,2025-09-15 07:24:11.470430,Lead Sponsor Name,Lokman Hekim University,Lokman Hekim Üniversitesi
NCT06450639,2025-09-22 07:24:44.677743,2025-09-15 07:24:11.470430,Last Update Post Date,2025-09-16,2025-08-15
NCT06450639,2025-10-20 07:24:46.633691,2025-10-13 07:24:44.496989,Last Update Post Date,2025-10-16,2025-09-16
NCT06450639,2025-11-10 07:23:57.616684,2025-11-03 07:24:26.813865,Last Update Post Date,2025-11-06,2025-10-16
NCT06606340,2025-09-15 07:24:11.470430,2025-09-08 07:23:27.695799,Last Update Post Date,2025-09-10,2024-09-23
NCT06643923,2025-09-22 07:24:44.677743,2025-09-15 07:24:11.470430,Lead Sponsor Name,Lokman Hekim University,Lokman Hekim Üniversitesi
NCT06756633,2025-09-22 07:24:44.677743,2025-09-15 07:24:11.470430,Lead Sponsor Name,Lokman Hekim University,Lokman Hekim Üniversitesi
NCT06817382,2025-09-22 07:24:44.677743,2025-09-15 07:24:11.470430,Start Date,2025-07-22,2025-05-31
NCT06817382,2025-09-22 07:24:44.677743,2025-09-15 07:24:11.470430,Last Update Post Date,2025-09-17,2025-06-03
NCT06817382,2025-09-29 07:24:18.405365,2025-09-22 07:24:44.677743,Last Update Post Date,2025-09-23,2025-09-17
NCT06817382,2025-11-03 07:24:26.813865,2025-10-27 07:23:55.233479,Last Update Post Date,2025-10-30,2025-09-23
NCT06867107,2025-09-15 07:24:11.470430,2025-09-08 07:23:27.695799,Overall Status,ENROLLING_BY_INVITATION,NOT_YET_RECRUITING
NCT06867107,2025-09-15 07:24:11.470430,2025-09-08 07:23:27.695799,Start Date,2025-08-20,2025-07-15
NCT06867107,2025-09-15 07:24:11.470430,2025-09-08 07:23:27.695799,Last Update Post Date,2025-09-10,2025-05-15
NCT06868784,2025-09-22 07:24:44.677743,2025-09-15 07:24:11.470430,Lead Sponsor Name,Lokman Hekim University,Lokman Hekim Üniversitesi
NCT06887491,2025-09-22 07:24:44.677743,2025-09-15 07:24:11.470430,Lead Sponsor Name,Lokman Hekim University,Lokman Hekim Üniversitesi
NCT07058662,2025-09-15 07:24:11.470430,2025-09-08 07:23:27.695799,Collaborator Name,"Shanghai Mianyi Biopharmaceutical Co., Ltd., Shanghai Xinzhi BioMed Co., Ltd., Belief BioMed Limited","Shanghai Mianyi Biopharmaceutical Co., Ltd., Shanghai Xinzhi BioMed Co., Ltd, Belief BioMed Limited"
NCT07127978,2025-09-15 07:24:11.470430,2025-09-08 07:23:27.695799,Condition,Duchene Muscular Dystrophy,"Duchene Muscular Dystrophy, Duchene&Amp;Amp;#39;s Muscular Dystrophy"
NCT07127978,2025-09-15 07:24:11.470430,2025-09-08 07:23:27.695799,Last Update Post Date,2025-09-10,2025-08-17
NCT07127978,2025-10-20 07:24:46.633691,2025-10-13 07:24:44.496989,Overall Status,RECRUITING,NOT_YET_RECRUITING
NCT07127978,2025-10-20 07:24:46.633691,2025-10-13 07:24:44.496989,Start Date,2025-10-31,2025-09-15
NCT07127978,2025-10-20 07:24:46.633691,2025-10-13 07:24:44.496989,Last Update Post Date,2025-10-16,2025-09-10
NCT07127978,2025-11-03 07:24:26.813865,2025-10-27 07:23:55.233479,Start Date,2025-10-23,2025-10-31
NCT07127978,2025-11-03 07:24:26.813865,2025-10-27 07:23:55.233479,Last Update Post Date,2025-10-30,2025-10-16
NCT07160634,2025-10-06 07:23:59.452506,2025-09-29 07:24:18.405365,Last Update Post Date,2025-10-02,2025-09-08
